SANTOS LTD/ AU000000STO6 /
2024-09-02 8:02:49 AM | Chg. +0.0310 | Volume | Bid9:25:01 AM | Ask9:25:01 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
4.3810EUR | +0.71% | 0 Turnover: 0.0000 |
4.3870Bid Size: 3,000 | 4.5530Ask Size: 3,000 | 14.6 bill.EUR | - | - |
GlobeNewswire
08-21
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic strok...
GlobeNewswire
08-20
Twenty-Three Sysco Delivery Partners Inducted Into the 2024 International Foodservice Distribution T...
GlobeNewswire
08-13
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
08-12
Valitor to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
GlobeNewswire
08-07
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Ma...
GlobeNewswire
08-01
Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership Conference
GlobeNewswire
07-17
Invixium Acquires Triax Technologies to Expand its Biometric Solutions with AI-based RTLS Offering f...
GlobeNewswire
06-27
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagi...
GlobeNewswire
06-26
Allergy Named Highest-Impact Journal in Allergy and Clinical Immunology for 2024